Neurotherapeutics

, Volume 11, Issue 2, pp 324–333

Genetic Biomarkers in Epilepsy

Review

DOI: 10.1007/s13311-014-0262-5

Cite this article as:
Weber, Y.G., Nies, A.T., Schwab, M. et al. Neurotherapeutics (2014) 11: 324. doi:10.1007/s13311-014-0262-5

Abstract

The identification of valid biomarkers for outcome prediction of diseases and improvement of drug response, as well as avoidance of side effects is an emerging field of interest in medicine. The concept of individualized therapy is becoming increasingly important in the treatment of patients with epilepsy, as predictive markers for disease prognosis and treatment outcome are still limited. Currently, the clinical decision process for selection of an antiepileptic drug (AED) is predominately based on the patient’s epileptic syndrome and side effect profiles of the AEDs, but not on effectiveness data. Although standard dosages of AEDs are used, supplemented, in part, by therapeutic monitoring, the response of an individual patient to a specific AED is generally unpredictable, and the standard care of patients in antiepileptic treatment is more or less based on trial and error. Therefore, there is an urgent need for valid predictive biomarkers to guide patient-tailored individualized treatment strategies in epilepsy, a research area that is still in its infancy. This review focuses on genomic factors as part of an individual concept for AED therapy summarizing examples that influence the prognosis of the disease and the response to AEDs, including side effects.

Keywords

HLASodium channelsSide effectPrognosisPharmaco-resistancePharmaco-response

Supplementary material

13311_2014_262_MOESM1_ESM.pdf (511 kb)
ESM 1(PDF 511 kb)

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2014

Authors and Affiliations

  1. 1.Department of Neurology and Epileptology, Hertie Institute for Clinical Brain ResearchUniversity of TübingenTübingenGermany
  2. 2.Dr. Margarete Fischer-Bosch Institute of Clinical PharmacologyStuttgartGermany
  3. 3.Department of Clinical PharmacologyUniversity HospitalTübingenGermany